AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
ANAVEX LIFE SCIENCES CORP.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 28, 2026
$1.25−0.06 (-4.58%)
Close on Oct 19, 2026
- Market cap
- $116.12B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
39.9%
37M of 93M shares
Institutional holders
179
24 new, 32 sold out
Net institutional buying
-3M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 6,671,075 | 8.10% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 4,663,459 | 5.03% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AVXL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,055,628 | 8.69% | $20.86M | +446,010 | 0.00% |
| Vanguard Capital Management LLC | 4,054,589 | 4.37% | $10.50M | +190,639 | 0.00% |
| Two Sigma Investments, LP | 3,046,538 | 3.29% | $7.89M | −201,350 | 0.01% |
| Geode Capital Management, LLC | 2,407,473 | 2.60% | $6.24M | +219,198 | 0.00% |
| State Street Corp | 1,922,770 | 2.07% | $4.98M | −2,589,258 | 0.00% |
| Federated Hermes, Inc. | 1,071,809 | 1.16% | $2.78M | +539,557 | 0.00% |
| Aqr Capital Management LLC | 963,014 | 1.04% | $2.49M | +206,222 | 0.00% |
| Vanguard Portfolio Management LLC | 948,633 | 1.02% | $2.46M | +165,485 | 0.00% |
| Summit Financial, LLC | 909,430 | 0.98% | $2.36M | −31,025 | 0.03% |
| Goldman Sachs Group Inc | 890,634 | 0.96% | $2.31M | +86,199 | 0.00% |
| Marshall Wace, Llp | 889,523 | 0.96% | $2.30M | +470,026 | 0.00% |
| Northern Trust Corp | 784,494 | 0.85% | $2.03M | +59,307 | 0.00% |
| Barclays PLC | 754,226 | 0.81% | $1.95M | +215,949 | 0.00% |
| Charles Schwab Investment Management Inc | 734,795 | 0.79% | $1.90M | −21,763 | 0.00% |
| Bank Of America Corp /De/ | 654,295 | 0.71% | $1.69M | −208,855 | 0.00% |
| Vanguard Fiduciary Trust Co | 621,451 | 0.67% | $1.61M | −25,718 | 0.00% |
| UBS Group AG | 620,374 | 0.67% | $1.61M | +50,418 | 0.00% |
| Private Advisor Group, LLC | 504,000 | 0.54% | $1.31M | +4,300 | 0.01% |
| LPL Financial LLC | 406,109 | 0.44% | $1.05M | −12,531 | 0.00% |
| Stifel Financial Corp | 332,597 | 0.36% | $861.43K | +95,793 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 179 | 37M | 39.9% | 24 / 64 | 56 / 32 | 4M | 7M |
| Q1 2026 | 190 | 40M | 43.1% | 38 / 75 | 46 / 29 | 12M | 5M |
| Q4 2025 | 185 | 38M | 40.9% | 29 / 60 | 55 / 27 | 8M | 2M |
| Q3 2025 | 186 | 33M | 35.5% | 27 / 57 | 49 / 17 | 3M | 2M |
| Q2 2025 | 178 | 33M | 35.1% | 24 / 69 | 34 / 25 | 3M | 2M |
| Q1 2025 | 181 | 31M | 33.9% | 39 / 59 | 43 / 25 | 5M | 3M |
| Q4 2024 | 168 | 30M | 31.9% | 47 / 50 | 39 / 22 | 5M | 2M |
| Q3 2024 | 145 | 27M | 29.2% | 24 / 47 | 29 / 19 | 10M | 3M |
| Q2 2024 | 141 | 27M | 29.0% | 21 / 42 | 43 / 26 | 3M | 9M |
| Q1 2024 | 147 | 33M | 35.2% | 17 / 53 | 43 / 23 | 8M | 2M |
| Q4 2023 | 153 | 26M | 28.5% | 27 / 56 | 36 / 17 | 3M | 2M |
| Q3 2023 | 143 | 25M | 27.0% | 13 / 53 | 47 / 14 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of AVXL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,925,439 | 3.16% | $7.58M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,417,982 | 2.61% | $6.26M | 0.01% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 2,045,098 | 2.21% | $5.62M | 0.25% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,041,514 | 1.12% | $2.70M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,002,575 | 1.08% | $2.76M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 737,460 | 0.80% | $1.91M | 0.01% | Jun 30, 2026 |
| iShares Biotechnology ETF | 631,748 | 0.68% | $1.64M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 484,708 | 0.52% | $1.47M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 450,282 | 0.49% | $1.36M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 440,209 | 0.47% | $1.33M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 310,051 | 0.33% | $803.03K | 0.05% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 266,123 | 0.29% | $806.35K | 0.00% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 224,867 | 0.24% | $618.38K | 0.01% | Jul 31, 2026 |
| Master Small Cap Index Series | 186,662 | 0.20% | $483.45K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 175,983 | 0.19% | $533.23K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christopher U. Missling | President and CEO, Director | 1,510,165 | 1.63% | Jan 9, 2026 |
| Sandra Boenisch | PFO & Treasurer | 67,963 | 0.07% | Sep 28, 2026 |
| Terrie Kellmeyer | Interim CEO | – | – | May 14, 2026 |
| Axel Paeger | Director | – | – | May 1, 2026 |
| Steffen Thomas | Director | 55,000 | 0.06% | Jun 9, 2025 |
| Peter D.O. Donhauser | Director | 5,000 | 0.01% | Apr 2, 2025 |
| Claus Vander Velden | Director | – | – | Apr 2, 2025 |
| Jiong Ma | Director | – | – | Apr 2, 2025 |
| Athanasios Skarpelos | Director | 1,306,458 | 1.41% | Apr 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Christopher U. Missling President and CEO, Director | Sep 11, 2025 | Tax withholding | −145,048 | $9.58 | $1.39M | 1,510,165 |
| Christopher U. Missling President and CEO, Director | Sep 11, 2025 | Option exercise | +187,500 | $5.04 | $945.00K | 1,655,213 |
| Steffen Thomas Director | Jun 5, 2025 | Option exercise | +50,000 | $1.76 | $88.00K | 55,000 |
| Steffen Thomas Director | Jun 5, 2025 | Tax withholding | −11,349 | $7.75 | $87.95K | 43,651 |
| Christopher U. Missling President and CEO, Director | Mar 24, 2025 | Option exercise | +500,000 | $0.92 | $460.00K | 1,750,210 |
| Christopher U. Missling President and CEO, Director | Mar 24, 2025 | Tax withholding | −282,497 | $9.63 | $2.72M | 1,467,713 |
| Peter D.O. Donhauser Director | Jun 14, 2024 | Buy | +2,835 | $3.64 | $10.32K | 5,000 |
| Steffen Thomas Director | May 15, 2024 | Buy | +5,000 | $4.52 | $22.60K | 5,000 |
| Christopher U. Missling President and CEO, Director | Mar 28, 2024 | Option exercise | +73,380 | $1.32 | $96.86K | 1,323,590 |
| Christopher U. Missling President and CEO, Director | Mar 28, 2024 | Sale | −73,380 | $5.11 | $374.97K | 1,250,210 |
| Christopher U. Missling President and CEO, Director | Jun 29, 2023 | Option exercise | +232,000 | $1.60 | $371.20K | 1,250,210 |
| Christopher U. Missling President and CEO, Director | Jun 28, 2023 | Option exercise | +268,000 | $1.60 | $428.80K | 1,286,210 |
| Christopher U. Missling President and CEO, Director | Jun 28, 2023 | Sale | −268,000 | $7.98 | $2.14M | 1,018,210 |
| Athanasios Skarpelos Director | May 25, 2022 | Sale | −50,000 | $9.06 | $453.00K | 1,306,458 |
| Athanasios Skarpelos Director | May 25, 2022 | Option exercise | +50,000 | $0.92 | $46.00K | 1,356,458 |
| Christopher U. Missling President and CEO, Director | Jun 29, 2021 | Option exercise | +51,620 | $1.32 | $68.14K | 1,069,830 |
| Christopher U. Missling President and CEO, Director | Jun 29, 2021 | Sale | −51,620 | $26.00 | $1.34M | 1,018,210 |
| Sandra Boenisch PFO and Treasurer | Jun 29, 2021 | Option exercise | +25,000 | $5.68 | $142.00K | 47,963 |
| Sandra Boenisch PFO and Treasurer | Jun 29, 2021 | Option exercise | +106,696 | $3.28 | $349.96K | 154,659 |
| Sandra Boenisch PFO and Treasurer | Jun 29, 2021 | Option exercise | +35,000 | $5.92 | $207.20K | 189,659 |
| Sandra Boenisch PFO and Treasurer | Jun 29, 2021 | Sale | −166,696 | $26.53 | $4.42M | 22,963 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +1,500 | $4.90 | $7.35K | 92,000 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +50,000 | $2.96 | $148.00K | 145,000 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +1,500 | $6.11 | $9.17K | 95,000 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +1,500 | $5.66 | $8.49K | 93,500 |
| Elliot Favus Director | May 21, 2021 | Sale | −145,000 | $11.70 | $1.70M | 0 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +1,500 | $5.57 | $8.36K | 90,500 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +1,500 | $5.64 | $8.46K | 89,000 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +50,000 | $0.92 | $46.00K | 87,500 |
| Elliot Favus Director | May 21, 2021 | Option exercise | +37,500 | $1.20 | $45.00K | 37,500 |
| Peter D.O. Donhauser Director | May 17, 2021 | Buy | +1,000 | $10.93 | $10.93K | 2,165 |
| Elliot Favus Director | Feb 24, 2021 | Option exercise | +45,500 | $2.58 | $117.39K | 45,000 |
| Elliot Favus Director | Feb 24, 2021 | Option exercise | +100,000 | $3.28 | $328.00K | 145,000 |
| Elliot Favus Director | Feb 24, 2021 | Sale | −145,500 | $12.66 | $1.84M | 0 |
| Peter D.O. Donhauser Director | Feb 19, 2021 | Buy | +165 | $12.97 | $2.14K | 1,165 |
| Peter D.O. Donhauser Director | Feb 19, 2021 | Buy | +1,000 | $12.62 | $12.62K | 1,000 |
| Christopher U. Missling President and CEO, Director | Mar 7, 2018 | Buy | +1,360 | $2.92 | $3.97K | 1,018,210 |
| Christopher U. Missling President and CEO, Director | Mar 6, 2018 | Buy | +1,450 | $2.73 | $3.96K | 1,016,850 |
| Christopher U. Missling President and CEO, Director | Mar 5, 2018 | Buy | +1,500 | $2.63 | $3.95K | 1,015,400 |
| Christopher U. Missling Director, President & CEO | Mar 2, 2018 | Buy | +1,650 | $2.41 | $3.98K | 1,013,900 |
| Christopher U. Missling President and CEO, Director | Oct 25, 2017 | Buy | +375 | $4.39 | $1.65K | 1,012,250 |
| Christopher U. Missling President and CEO, Director | Oct 24, 2017 | Buy | +375 | $4.92 | $1.85K | 1,011,875 |
| Christopher U. Missling President and CEO, Director | Oct 19, 2017 | Buy | +375 | $4.49 | $1.68K | 1,011,500 |
| Christopher U. Missling President and CEO, Director | Oct 17, 2017 | Buy | +375 | $4.27 | $1.60K | 1,011,125 |
| Christopher U. Missling President and CEO, Director | Oct 13, 2017 | Buy | +750 | $4.22 | $3.17K | 1,010,750 |
| Christopher U. Missling President and CEO, Director | Oct 5, 2017 | Buy | +375 | $4.30 | $1.61K | 1,010,000 |
| Christopher U. Missling President and CEO, Director | Oct 2, 2017 | Buy | +375 | $4.20 | $1.58K | 1,009,625 |
| Christopher U. Missling President and CEO, Director | Sep 28, 2017 | Buy | +375 | $4.21 | $1.58K | 1,009,250 |
| Christopher U. Missling President and CEO, Director | Sep 26, 2017 | Buy | +375 | $3.88 | $1.46K | 1,008,875 |
| Christopher U. Missling President and CEO, Director | Sep 20, 2017 | Buy | +375 | $4.23 | $1.59K | 1,008,500 |
| Christopher U. Missling President and CEO, Director | Sep 18, 2017 | Buy | +375 | $4.40 | $1.65K | 1,008,125 |
| Christopher U. Missling President and CEO, Director | Sep 14, 2017 | Buy | +375 | $4.58 | $1.72K | 1,007,750 |
| Christopher U. Missling President and CEO, Director | Sep 11, 2017 | Buy | +375 | $4.81 | $1.80K | 1,007,375 |
| Christopher U. Missling President and CEO, Director | Sep 7, 2017 | Buy | +375 | $4.76 | $1.79K | 1,007,000 |
| Christopher U. Missling President and CEO, Director | Sep 5, 2017 | Buy | +375 | $4.90 | $1.84K | 1,006,625 |
| Christopher U. Missling President and CEO, Director | Aug 31, 2017 | Buy | +375 | $4.48 | $1.68K | 1,006,250 |
| Christopher U. Missling President and CEO, Director | Aug 28, 2017 | Buy | +375 | $4.44 | $1.67K | 1,005,875 |
| Christopher U. Missling President and CEO, Director | Aug 24, 2017 | Buy | +375 | $4.54 | $1.70K | 1,005,500 |
| Christopher U. Missling President and CEO, Director | Aug 21, 2017 | Buy | +375 | $4.07 | $1.53K | 1,005,125 |
| Christopher U. Missling President and CEO, Director | Aug 18, 2017 | Buy | +375 | $3.81 | $1.43K | 1,004,750 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Christopher U. Missling Officer | Mar 28, 2024 | 73,380 | $371.30K | Mar 28, 2024 | Exercised Stock Options |
| Christopher U. Missling Officer | Jun 28, 2023 | 268,000 | $2.14M | Jun 28, 2023 | Stock Option Exercise |